Combining Genomic Profiling and Tissue-Based Biomarker Assays to Aid in the Early Detection and Prevention of Cancer

Genomic sequencing of precancerous lesions to improve prevention and early detection of cancer was a major focus at the recent American Association of Cancer Research (AACR) annual meeting.

With new immunotherapy targets continuing to emerge, and with the ongoing development of combination therapies, including targeted therapies, chemotherapy, radiation therapy, and checkpoint inhibitors, understanding the stromal components and immune infiltrates in tissue may be key to enabling a precise and targeted therapeutic strategy for cancer prevention and early intervention[…]

Read More

The Role of cTA™ In Bringing IO 360° Full Circle

The 3rd annual Immuno-Oncology 360° meeting, #IO360nyc, took a 360-degree view of the IO space with the first day dedicated to science, the second to clinical data, and the third to the “business” landscape. 

With over 800 clinical trials in process for combination IO therapeutics and almost no holds for toxic events, it is estimated that approximately 80 FDA approvals will be issued over the next two to four years[…]

Read More